Trial Profile

Safety, Tolerability and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Once-weekly Rifapentine and Isoniazid (3HP) Among Infants, Children and Adolescents Living With HIV Taking Dolutegravir-based Antiretroviral Treatment

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Dolutegravir/lamivudine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Isoniazid; Lamivudine/abacavir; Rifapentine
Indications HIV-1 infections
Focus Pharmacokinetics
Acronyms DOLPHIN KIDS

01 Jun 2023 Planned End Date changed from 31 Dec 2023 to 1 Dec 2025.
01 Jun 2023 Planned primary completion date changed from 31 Dec 2023 to 1 Dec 2024.
01 Jun 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com